Thoughts, Words, Action: The Alma-Ata Declaration to Diabetes Care Transformation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Thoughts, Words, Action: The Alma-Ata Declaration to Diabetes Care Transformation ; volume:9 ; number:3 ; day:9 ; month:5 ; year:2018 ; pages:873-876 ; date:6.2018
Diabetes therapy ; 9, Heft 3 (9.5.2018), 873-876, 6.2018
- Classification
-
Medizin, Gesundheit
- Creator
-
Kalra, Sanjay
- Contributor
-
Akanov, Zhanay A.
Pleshkova, Alex Y.
SpringerLink (Online service)
- DOI
-
10.1007/s13300-018-0440-2
- URN
-
urn:nbn:de:101:1-2018081511303750957296
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kalra, Sanjay
- Akanov, Zhanay A.
- Pleshkova, Alex Y.
- SpringerLink (Online service)
Other Objects (12)
Equipoise Is a Slippery Eel
Mishti copes with diabetes: A pragmatic approach to coping skills training
Diabetes: Exploring social and psychological domain
Mishti copes with diabetes: Dancing
Higher, sweeter, heavier: Not necessarily healthier
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Discrimination and diabetes: Insight from the second Diabetes Attitudes Wishes and Needs (DAWN2) Study
Therapy in type 2 diabetes: A logical empiricism - based approach
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
The alcohol and tobacco burden of India
Equipoise Is a Slippery Eel
Mishti copes with diabetes: A pragmatic approach to coping skills training
Diabetes: Exploring social and psychological domain
Mishti copes with diabetes: Dancing
Higher, sweeter, heavier: Not necessarily healthier
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Discrimination and diabetes: Insight from the second Diabetes Attitudes Wishes and Needs (DAWN2) Study
Therapy in type 2 diabetes: A logical empiricism - based approach
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
The alcohol and tobacco burden of India
Equipoise Is a Slippery Eel
Mishti copes with diabetes: A pragmatic approach to coping skills training
Diabetes: Exploring social and psychological domain
Mishti copes with diabetes: Dancing
Higher, sweeter, heavier: Not necessarily healthier
Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Discrimination and diabetes: Insight from the second Diabetes Attitudes Wishes and Needs (DAWN2) Study
Therapy in type 2 diabetes: A logical empiricism - based approach
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes